Table 5.
Current phase III trials for treatment of gastric cancer.
| Trial | Treatment setting | Treatment arms | Number of patients required |
|---|---|---|---|
| CRITICS Dutch Colorectal Cancer Group | Stage Ib-IV gastric cancer | Perioperative ECC (threecycles pre and post) | 788 |
| Neo-adjuvant ECC (threecycles), surgery, then adjuvant CC CRT | |||
| Magic-B British MRC | Stage Ib-IV resectable adenocarcinoma of the stomach or Type III GEJ | Perioperative ECC (three cyclespre- and post-) | 1100 |
| Perioperative ECC plus bevacizumab (three cycles pre- and post-) Maintenance bevacizumab 6x | |||
| ARTIST | ≥D2 resected stage | Adjuvant CC | 490 |
| Samsung Medical Centre NCT00323830 | Ib-IV gastric cancer | Adjuvant CC CRT | |
| Intergroup CALGB 80101 (completed) | Stage Ib-IV resected adenocarcinoma of the stomach or GEJ | Adjuvant 5-FU CRT Adjuvant ECF CRT |
824 |
| Tokyo Metropolitan Oncology Group (NCT00687843) |
Stage II-IIIB gastric cancer | Adjuvant Tegafur-gimeracil-oteracil (TS-1) | 480 |
| Adjuvant TS-1 + PSK (Krestin) | |||
| Hokuriku-Kinki Immunochemotherapy Study Group (NCT00216034) | Stage II-IIIA gastric cancer | Adjuvant Tegafur-gimeracil-oteracil (TS-1) Adjuvant TS-1 + PSK (Krestin) |
280 |
| Japan Clinical Oncology Group JCOG 0501 (NCT00252161) |
Borrmann Type 4 and Large Type 3 Gastric Cancer |
≥D2 resection alone Neoadjuvant S-1 plus cisplatinthen ≥D2 resection |
300 |
| CLASSIC | Stage II-IIIb gastric cancer | D2 resection | 1024 |
| Sanofi-Aventis, South Korea | D2 resection, adjuvant capecitabine, oxiplatin | ||
Explanations of acronyms: ECC: epirubicin, cisplatin, capecitabine; CC: cisplatin, capecitabine; CRT: chemoradiotherapy; GEJ: gastroesophageal junction; 5-FU: 5-fluorouracil; ECF: epirubicin, cisplatin, 5-FU